前列地尔联合依那普利对早期糖尿病肾病患者血清超敏C反应蛋白及胱抑素的影响

目的:探讨前列地尔联合依那普利在治疗早期糖尿病肾病中对患者血清超敏C反应蛋白及胱抑素水平的影响。方法:将我院115例早期糖尿病肾病患者随机分为3组:前列地尔组37例,给予前列地尔10μg+0.9%氯化钠注射液100 mL,静脉滴注,qd;依那普利组38例,口服依那普利5 mg,bid;联合治疗组40例,给予前列地尔+依那普利(用法用量同其他2组)。全部病例均观察4周。分别比较3组血压、血糖、糖化血红蛋白(HbA1c)、尿微量白蛋白排泄率(UAER)、超敏C反应蛋白(hs-CRP)、胱抑素(Cys C)水平的变化。结果:治疗后3组中hs-CRP、Cys C及24hUAER均较治疗前明显好转(P<0.05)。治疗后,联合治疗组hs-CRP、CysC及24hUAER均较其他2组改善更明显(P<0.05)。结论:前列地尔联合依那普利治疗早期糖尿病肾病疗效较好,且能降低血清hs-CRP及24hUAER血清Cys C水平。

Effects of Treatment of Enalaprilat Combined with Alprostadil on Hypersensitivity C-Reaction Protein and Cystatin in Early Diabetic Nephropathy Patients

OBJECTIVE： To evaluate the effects of alprostadil combined with enalaprilat on serum hypersensitivity C-reactive protein and cystatin （Cys C） level in early diabetic nephropathy patients. METHODS： 115 patients with early diabetic nephropathy in our hospital were randomly divided into 3 groups： 37 cases in alprostadil group received alprostadil 10 μg＋sodium chloride injection 100 mL i.v. gtt, qd; 38 cases in enalaprilat group received enalaprilat 5 mg, bid; 40 cases in combination group received alprostadil 10 μg i.v. gtt, qd and enalaprilat 5 mg, bid. All cases were under observation for 12 weeks. 3 groups were compared in respects of blood pressure, blood sugar, glycated hemoglobin （HbAlc）, microalbuminuria excretion rate （UAER）, hs-CRP level and Cys C levels. RESULTS： After treatment, hs-CRP, Cys C and 24hUAER in 3 groups were improved significantly （P〈0.05）. After treatment, the improvement of hs-CRP, Cys C and 24hUAER of combination group were more significant than other 2 groups （P〈0.05）. CONCLUSION： Alprostadil combined with enalaprilat is effective for the therapy of early diabetic nephropathy and can reduce serum sensitivity C-reactive protein and 24hUAER and serum hs-CRP.